Opendata, web and dolomites


Integrated drug discovery approach to generate brain-penetrant inhibitors of glioblastoma cell proliferation

Total Cost €


EC-Contrib. €






Project "BRAINHIB" data sheet

The following table provides information about the project.


Organization address
postcode: EH8 9YL

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-02-29


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) coordinator 183˙454.00


 Project objective

Glioblastoma multiforme (GBM) is the most common and aggressive cancer that begins within the brain. Without treatment the average survival following diagnosis is merely 3 months. Although clinically-approved kinase inhibitors present promising features to treat GBM, most of them do not cross the blood brain barrier (BBB), impeding their clinical use in GBM patients. We propose an agile approach that combines ligand-based drug design of highly-focused compound libraries and first-in-class phenotypic assay for simultaneous screening of BBB penetration, unspecific toxicity and anticancer properties, in an iterative manner. This approach will allow a one-step selection of hit / lead compounds from in-house generated compound libraries that cross the BBB to accelerate the design of CNS-active anticancer drugs. Furthermore, the use of chemical proteomics and the state-of-the-art proteomics techniques will facilitate the identification of the kinases and / or pathways that are involved in the observed phenotype, which could result in the discovery of novel GBM oncotargets and unknown modes of action. This highly innovative integrated approach has the potential to speed up preclinical drug discovery efforts in CNS diseases, and in doing so, promote European Scientific Excellence. As a developer and provider of such tools, the applicant will be positioned in a privileged position for starting cross-disciplinary collaborations with academics and Pharma across Europe and for establishing herself as an independent researcher.


year authors and title journal last update
List of publications.
2020 Teresa Valero, Daniel J. Baillache, Craig Fraser, Samuel H. Myers, Asier Unciti-Broceta
Pyrazolopyrimide library screening in glioma cells discovers highly potent antiproliferative leads that target the PI3K/mTOR pathway
published pages: 115215, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2019.115215
Bioorganic & Medicinal Chemistry 28/1 2020-04-01

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINHIB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRAINHIB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

InProSMod (2021)

Cholinergic and NMDAR-dependent recruitment of Layer 1 Interneuron shapes cortical motor Processing through network States Modulation

Read More  

NeoPur (2019)

New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.

Read More  

The Damned (2020)

Algeria, antifascism, and Third Worldism: An anticolonial genealogy of the Western European New Left (Algeria, France, Italy, 1957-1975)

Read More